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isation due to treatment constraints (27%) and giving 
up leasure and social activities (22%). As a consequence,
her psychology is altered with anxiety and anguish 
(45%) and fear of be unable to cope (42%) and so
medical and/or psychological help is often needed by the
spouse (42%). CONCLUSION: COMPAS underlines the
spouse’s needs for information concerning: the disease
and its evolution, the current and future treament, but
also a concrete daily help adapted to the level of the
dependance of the patient.
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OBJECTIVE: To evaluate the linguistic validity of the
Swedish version of a British health status questionnaire
for Parkinson’s disease (PD), the 39-item PD Question-
naire (PDQ-39). METHODS: Nine consecutive non-
demented PD patients (mean age: 59.2, b10.1 yrs; median
Hoehn and Yahr stage of PD: III [range: II-V]) and 3 PD
specialized clinicians (1 neurologist, 2 nurses) were given
a copy of the Swedish version of the PDQ-39. Each ques-
tionnaire item relates to a frame question (“Due to having
Parkinson’s disease, how often during the last month have
you . . . ?”), appearing at the top of each questionnaire
page. For each item, respondents are requested to afﬁrm
1 of 5 response categories: “never”, “occasionally”,
“sometimes”, “often”, or “always”. Subjects commented
on each PDQ-39 section and item as they carefully read
(all subjects) and responded to (patients only) the ques-
tionnaire. All comments and responses were recorded and
reviewed for accuracy at the end of each interview.
RESULTS: Three aspects of the questionnaire were found
particularly problematic: the frame question, the response
options and 2 out of 3 items in the Social Support (SOC)
subscale. Problems with the frame question related
mainly to its anonymity, with patients failing to take it
into consideration when reading the items, which (as
several patients acknowledged) may have affected their
responses. The distinction between the different response
alternatives, particularly “sometimes” and “occasion-
ally”, was found unclear by ﬁve patients and one clini-
cian. The main problem with the two items of the SOC
was a double negative in the wording, which was prob-
lematic for most patients and caused some to give the
opposite answer to that intended. CONCLUSIONS: This
preliminary study illustrates the need for documented lin-
guistic validity before patient-reported outcome measures
can be considered suitable for use in clinical trials,
research, and health economic evaluations.
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OBJECTIVES: A cross-sectional survey was conducted 
to understand the burdens experienced by caregivers of
people with Alzheimer’s disease (AD). The effects of 
three cholinesterase inhibitors—rivastigmine, donepezil
and galantamine—on caregiver burden were compared.
METHODS: Caregivers of people with AD, identiﬁed
from a nationwide consumer list, were evaluated using
the Caregiver Burden Scale (CBS)—a Likert-type scale
(score range, 1–4). All patients were receiving rivastig-
mine, donepezil or galantamine. CBS data assessing
burden across 15 caregiving tasks were examined. Sepa-
rate linear regression models were run for: overall burden
score; direct care; instrumental care (providing trans-
portation; managing ﬁnances; performing additional
tasks; structuring/planning activities; providing child
care, elder care or pet care; managing services and
resources); and interpersonal care (providing emotional
support; watching for and reporting symptoms; manag-
ing behavioral problems). RESULTS: Compared with
caregivers of donepezil users (n = 805), caregivers of
rivastigmine users (n = 175) experienced signiﬁcantly less
burden (lower CBS scores). Total CBS scores were 0.163
points lower with rivastigmine vs donepezil (p = 0.018),
and individual CBS item scores for instrumental and
interpersonal care were both 0.194 points lower with
rivastigmine (p = 0.018 and p = 0.014, respectively). Sim-
ilarly, compared with caregivers of galantamine-users 
(n = 102), caregivers of rivastigmine-users experienced
signiﬁcantly less caregiver burden (-0.364, p = 0.001),
especially in instrumental (-0.439, p = 0.001) and inter-
personal care (-0.392, p = 0.003). Direct care scores were
also numerically superior in the rivastigmine groups com-
pared with donepezil (-0.039) or galantamine (-0.114),
but not statistically signiﬁcantly so. CONCLUSIONS:
Rivastigmine may have a more positive impact on care-
giver burden in AD than donepezil or galantamine. In
particular, rivastigmine appears to have greater effects on
interpersonal and instrumental care, both of which are
important contributors to caregiver burden and patient
institutionalization. The beneﬁts of rivastigmine treat-
ment may enable patients to remain at home for longer,
improving patients’ and caregivers’ quality of life, and
could minimize institute onal costs.
